KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Invested Capital (2016 - 2025)

NovoCure (NVCR) has disclosed Invested Capital for 12 consecutive years, with $340.5 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 5.47% to $340.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $340.5 million through Dec 2025, down 5.47% year-over-year, with the annual reading at $340.5 million for FY2025, 5.47% down from the prior year.
  • Invested Capital hit $340.5 million in Q4 2025 for NovoCure, roughly flat from $341.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.0 billion in Q3 2022 to a low of $340.5 million in Q4 2025.
  • Historically, Invested Capital has averaged $728.5 million across 5 years, with a median of $931.5 million in 2021.
  • Biggest five-year swings in Invested Capital: soared 285.09% in 2021 and later plummeted 62.48% in 2024.
  • Year by year, Invested Capital stood at $972.7 million in 2021, then rose by 3.49% to $1.0 billion in 2022, then decreased by 7.49% to $931.3 million in 2023, then tumbled by 61.33% to $360.2 million in 2024, then decreased by 5.47% to $340.5 million in 2025.
  • Business Quant data shows Invested Capital for NVCR at $340.5 million in Q4 2025, $341.3 million in Q3 2025, and $349.4 million in Q2 2025.